SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on June 26, 2024, reporting events occurring on June 24, 2024. The Company is incorporated in Delaware and its common stock (Symbol: BSGM) was previously listed on The NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory status and listing events rather than financial performance.
Material Changes
- Delisting Confirmation: On June 24, 2024, the Nasdaq Hearings Panel declined to reconsider its June 10, 2024 decision to delist the Company's common stock.
- Trading Suspension: Trading on Nasdaq was suspended effective June 12, 2024.
- Current Trading Venue: Following suspension, the stock became eligible to trade on the OTC Market's Pink Current Information tier.
- Appeal Filed: On June 25, 2024, the Company appealed the delisting determination to the Nasdaq Listing and Hearing Review Council.
Outlook, Risks, and Management Commentary
Management is actively seeking approval to trade on the OTC Market's OTCQB trading platform, which is a higher tier than the current Pink Current Information status. The Company plans to provide updates regarding the appeal effort as material events occur. The primary risk identified is the continued loss of Nasdaq listing status and the associated liquidity and visibility implications of trading on the OTC markets.
Investor Verification Checklist
- Verify the current trading status and ticker symbol on the OTC Markets (Pink Current Information vs. OTCQB).
- Monitor the outcome of the appeal filed with the Nasdaq Listing and Hearing Review Council.
- Review the specific Nasdaq listing rule deficiencies that led to the initial delisting decision.
- Confirm if the Company has filed any subsequent 8-Ks regarding the appeal status or OTCQB approval.